Loading...
•
Nov 30, 2024
AngioDynamics Q2 2025 Earnings Report
Achieved strong performance driven by Med Tech segment growth and key milestones for NanoKnife System.
Key Takeaways
AngioDynamics reported a 9.2% increase in net sales to $73.0 million, driven by a 25% increase in Med Tech sales. The company achieved adjusted EBITDA of $3.1 million and a GAAP loss per share of $(0.26). They also received CPT Category I Codes for IRE and FDA 510(k) clearance for NanoKnife Prostate Tissue Ablation.
Net sales increased by 9.2% to $73.0 million.
Med Tech net sales grew by 25.0% to $31.5 million.
Received CPT Category I Codes for Irreversible Electroporation (IRE).
Received FDA 510(k) clearance for NanoKnife Prostate Tissue Ablation.
AngioDynamics
AngioDynamics
AngioDynamics Revenue by Segment
AngioDynamics Revenue by Geographic Location
Revenue by Segment
Med Tech Revenue
CapyFin.comMed Device Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
AngioDynamics provided fiscal year 2025 financial guidance, expecting net sales to be in the range of $282 to $288 million, Med Tech net sales to grow in the range of 12% to 15%, and Med Device net sales to be flat. Adjusted EBITDA is expected to be in the range of $1.0 to $3.0 million, and Adjusted loss per share in the range of $0.34 to $0.38.
Positive Outlook
- Net sales expected to be in the range of $282 to $288 million, representing growth of between 4.2% – 6.4% over fiscal 2024 pro forma revenue of $270.7 million
- Med Tech net sales to grow in the range of 12% to 15%, an increase from 10% to 12%
- Adjusted EBITDA in the range of $1.0 to $3.0 million, an increase from the previous guidance of a loss of $2.5 million to $0
- Adjusted loss per share in the range of $0.34 to $0.38, an improvement from the previous guidance of a loss per share of $0.38 to $0.42
- Gross margin to be approximately 52% to 53%
Challenges Ahead
- Med Device net sales to be flat, a decrease from 1% to 3%
- Expecting to utilize cash in the third fiscal quarter
- Expecting to generate cash in the fourth fiscal quarter
- GAAP net loss of $10.7 million
- Gross margin for the Med Device business was 47.8%, a decrease of 240 basis points compared to the second quarter of fiscal 2024 due to inflationary pressures and costs associated with the transition to outsourced manufacturing
Revenue & Expenses
Visualization of income flow from segment revenue to net income